Sign in

CIK 0001789972

  • Non-accelerated filer
  • Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813879991
Phone
+1 617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Grant or award Director acquired 100,699 shares (grant or award)
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 4 Planned sale Chief Scientific Officer sold 63,606 shares at an average $28.25 ($1,796,676)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
  9. 4 Grant or award President and CEO acquired 160,000 shares (grant or award)
  10. 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
  11. 4 Grant or award Chief Medical Officer acquired 62,500 shares (grant or award)
  12. 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
  13. 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
  14. 4 Planned sale Chief Business Officer sold 40,000 shares at $16.18 ($647,200)
  15. 4 Planned sale Chief Business Officer sold 40,000 shares at $14.09 ($563,600)
  16. 4 Planned sale Chief Business Officer sold 40,000 shares at an average $12.31 ($492,508)
  17. 4 Open-market sale President and CEO sold 4,272 shares at $9.24 ($39,473)
  18. 4 Open-market sale Chief Medical Officer sold 1,860 shares at $8.50 ($15,810)
  19. 4 Open-market sale Chief Legal Officer sold 1,400 shares at $8.50 ($11,900)
  20. 4 Open-market sale Chief Financial Officer sold 1,920 shares at $8.50 ($16,320)

Page 5 of 13 · 253 filings